Head and Neck Cancer (Salivary Gland)

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    AR AR positivity
    86% SDC, 26% Ac NOS, 15% AcCC, 5% MEC, 5% ACC (1)
    Androgen deprivation therapy (ADT):
    mPFS 3.8 mo, mOS 4 mo (2)
    Phase 2 bicalutamide (anti-androgen) with leuprorelin (GnRH agonist): ORR 42%, mPFS 8.8 mo, mOS 30.5 mo (3)
    Bicalutamide (anti-androgen) alone or with goserelin (LHRH agonist) or leuprolide (LHRH agonist): ORR 25%–50% (4)
    Bicalutamide (anti-androgen) with triptorelin (LHRH agonist): ORR 65%, PFS 12%, 5-yr OS 19% (5)
    NTRK ETV6-NTRK3 fusion
    15% AcCC (6), ry analogue secretory carcinoma of salivary glands (MASC) (7)
    Other topics in Targets by Organ Site